晶泰控股已收到与DoveTree订立的最终协议项下约定的5100万美元的首付款

Core Viewpoint - JingTai Holdings (02228) has entered into a final agreement with DoveTree Medicines LLC and its affiliates to utilize its AI and robotics-based drug discovery platform for developing drug candidates targeting oncology, immunology, inflammation, neurological disorders, and metabolic disorders [1] Group 1 - The agreement allows JingTai to discover and develop small molecule and antibody candidates for multiple key targets selected by DoveTree [1] - DoveTree will receive exclusive global development and commercialization rights for the products developed under this agreement [1] - As of the announcement date, JingTai has received an initial payment of $51 million under the terms of the final agreement [1]